Paper29664018
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.
Zheng X and 19 others. J Clin Invest, 2018. Cited by 210 papers, by iCite.
Cite this record
ConductScience Library. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Papers, record 29664018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29664018
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD8-Positive T-Lymphocytes | Major topic |
| Colonic Neoplasms | Major topic |
| Lymphocyte Depletion | Major topic |
| Mammary Neoplasms, Experimental | Major topic |
| Perfusion | Major topic |
| Animals | |
| Interferon-gamma | |
| Mice |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| R01 NS104315 | NINDS NIH HHS | United States | R01NS104315 | PubMed and NIH | NIH RePORTER |
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16916931 | A2A adenosine receptor protects tumors from antitumor T cells. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16916931 | PubMed |
| 2 | 24990240 | Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24990240 | PubMed |
| 3 | 18418378 | Vascular normalization in Rgs5-deficient tumours promotes immune destruction. | Nature | 2008 | https://conductscience.org/library/papers/18418378 | PubMed |
| 4 | 22205687 | Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22205687 | PubMed |
| 5 | 26936508 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/26936508 | PubMed |
| 6 | 24190997 | Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24190997 | PubMed |
| 7 | 26433815 | PD-L1 expression as a potential predictive biomarker. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26433815 | PubMed |
| 8 | 27079802 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27079802 | PubMed |
| 9 | 20516446 | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20516446 | PubMed |
| 10 | 15701862 | Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15701862 | PubMed |
| 11 | 15637262 | Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. | Science | 2005 | https://conductscience.org/library/papers/15637262 | PubMed |
| 12 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 13 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
| 14 | 23390376 | CTLA-4 blockade in tumor models: an overview of preclinical and translational research. | Cancer Immun | 2013 | https://conductscience.org/library/papers/23390376 | PubMed |
| 15 | 19201652 | T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. | Trends Immunol | 2009 | https://conductscience.org/library/papers/19201652 | PubMed |
| 16 | 22547817 | Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22547817 | PubMed |
| 17 | 25307346 | Interferon-γ safeguards blood-brain barrier during experimental autoimmune encephalomyelitis. | Am J Pathol | 2014 | https://conductscience.org/library/papers/25307346 | PubMed |
| 18 | 28046063 | Three-Dimensional High-Frequency Ultrasonography for Early Detection and Characterization of Embryo Implantation Site Development in the Mouse. | PLoS One | 2017 | https://conductscience.org/library/papers/28046063 | PubMed |
| 19 | 23752227 | Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. | J Exp Med | 2013 | https://conductscience.org/library/papers/23752227 | PubMed |
| 20 | 25838373 | The future of immune checkpoint therapy. | Science | 2015 | https://conductscience.org/library/papers/25838373 | PubMed |
Cited by160
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957962 | Human Intravital Microscopy. | Methods Mol Biol | 2027 | https://conductscience.org/library/papers/42957962 | PubMed |
| 42806957 | Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy. | J Transl Res | 2026 | https://conductscience.org/library/papers/42806957 | PubMed |
| 42538573 | CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model. | Cancer Imaging | 2026 | https://conductscience.org/library/papers/42538573 | PubMed |
| 42505204 | Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42505204 | PubMed |
| 42396187 | Anlotinib Combined with Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 9 Hydrochloride Suppresses Colorectal Cancer Progression by Inducing Neovascularization and Reprogramming the Tumor Immune Microenvironment in MSS Murine Model. | Immunotargets Ther | 2026 | https://conductscience.org/library/papers/42396187 | PubMed |
| 42312195 | Identification of chondroitin polymerizing factor as a biomarker for predicting immunotherapy response in breast cancer: a bioinformatics analysis of tumor microenvironment. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42312195 | PubMed |
| 42204346 | Poorly perfused tumor regions harbor T cells with a glucose-dependent effector phenotype. | EMBO Rep | 2026 | https://conductscience.org/library/papers/42204346 | PubMed |
| 41997128 | Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature. | Cell | 2026 | https://conductscience.org/library/papers/41997128 | PubMed |
| 41808840 | Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation. | Front Immunol | 2026 | https://conductscience.org/library/papers/41808840 | PubMed |
| 41692709 | Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41692709 | PubMed |
| 41673720 | Vascular abnormalization confers tumor resistance to antiangiogenic therapy via downregulating angiostatic factors. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/41673720 | PubMed |
| 41665856 | A mechanical reprogramming: synergistic tumor microenvironment normalization improves nano-immunotherapy delivery in prostate cancer via multiphysics modeling. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/41665856 | PubMed |
| 41584574 | Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer. | Front Oncol | 2025 | https://conductscience.org/library/papers/41584574 | PubMed |
| 41556173 | Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy. | Int J Surg | 2026 | https://conductscience.org/library/papers/41556173 | PubMed |
| 41402130 | Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer. | Future Oncol | 2026 | https://conductscience.org/library/papers/41402130 | PubMed |
| 41358269 | Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/41358269 | PubMed |
| 41313745 | Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41313745 | PubMed |
| 41229377 | Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41229377 | PubMed |
| 41133010 | Multi-institutional development and validation of habitat imaging for predicting outcomes of first-line immunotherapy in advanced non-small cell lung cancer. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41133010 | PubMed |
| 40579467 | Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy. | Nat Rev Immunol | 2025 | https://conductscience.org/library/papers/40579467 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29664018
GET https://conductscience.org/api/papers/v1/29664018/references?page=2